IPO

The company is developing a blood-based test to detect more than 50 cancer types across all stages and identify a tumor's tissue of origin.

The firm intends to use about $25 million to $30 million of the net proceeds for the continued development and planned commercialization of its KidneyIntelX platform.

The company said it anticipates using about $25 million to $30 million of the net proceeds for the continued development of its KidneyIntelX platform.

The company sells a number of next-generation sequencing-based tissue and liquid biopsy tests for cancer therapy selection to the Chinese market.

Progenity recently agreed to pay millions to three major insurers under settlement agreements related to allegations over undisclosed past business practices.

The firm has granted the underwriters an option to purchase up to 2,400,000 additional shares, which would contribute additional gross proceeds of up to $38.4 million.

The company recently agreed to pay millions to three major insurers under settlement agreements related to allegations over undisclosed past business practices.

The Beijing-based company offers genomics products and services, including PCR instruments and cancer sequencing, and maintains a research center in the US.

ArcherDx has leveraged next-generation sequencing to develop and commercialize more than 325 research-use-only products and a pan-solid tumor diagnostic test.